Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Selexipag - Actelion/Nippon Shinyaku

Drug Profile

Selexipag - Actelion/Nippon Shinyaku

Alternative Names: ACT-293987; NS-304; Uptravi

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nippon Shinyaku
  • Developer Actelion Pharmaceuticals; Nippon Shinyaku
  • Class Acetamides; Antihypertensives; Pyrazines; Small molecules; Sulfonamides; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension
  • Phase III Arteriosclerosis obliterans; Pulmonary hypertension
  • Phase II Raynaud's disease; Spinal stenosis

Most Recent Events

  • 05 Oct 2018 Actelion plans a phase III SELECT trial for Pulmonary hypertension in January 2019 (PO) (NCT03689244) (EudraCT2018-002823-41)
  • 25 Aug 2018 Adverse events data from a phase III GRIPHON and its extension trial in Pulmonary arterial hypertension presented at the Annual Congress of the European Society of Cardiology (ESC-card 2018)
  • 25 Jul 2018 Phase-II clinical trials in Pulmonary arterial hypertension (In children, In adolescents) in Hungary (PO) (NCT03492177)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top